Role of chemoradiotherapy in oesophageal cancer - adjuvant and neoadjuvant therapy

Clinical Oncology

Volumn 26, Issue 9, 2014, Pages 522-532

  Gwynne, S ^a   Wijnhoven, B P L ^b   Hulshof, M ^c   Bateman, A ^d  

^a SINGLETON HOSPITAL   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adjuvant; Chemoradiotherapy; Neoadjuvant; Oesophagus

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; PLATINUM;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; ESOPHAGEAL NEOPLASMS; PROCEDURES;

CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY;

EID: 84905569724     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.05.015     Document Type: Article

References (55)

1. Pottgen C., Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer - a meta-analysis of the randomized trials. Cancer Treatment Rev 2012, 38:599-604.
2. Gwynne S., Falk S., Gollins S., et al. Oesophageal chemoradiotherapy in the UK - current practice and future directions. Clin Oncol 2013, 25:368-377.
3. Boone J., Livestro D.P., Elias S.G., et al. International survey on esophageal cancer: part II staging and neoadjuvant therapy. Dis Esophagus 2009, 22:203-210.
4. Medical Research Council Oesophageal Cancer Working Party Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733.
5. Hingorani M., Crosby T., Maraveyas A., et al. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer - do we need another randomised trial?. Clin Oncol 2011, 23:696-705.
6. van Hagen P., Hulshof M.C.C.M., van Lanschot J.J.B., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
7. Fok M., Sham J.S.T., Choy D., et al. Postoperative radiotherapy for carcinoma of the oesophagus. Surgery 1993, 113:138-147.
8. Zieren H.U., Muller J.M., Jacobi C.A., et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic oesophagus: a prospective randomised study. World J Surg 1995, 19:444-449.
9. Teniere P.H.J., Fingerhut A., Fagniez P.L. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower oesophagus as shown by a multicentre controlled trial. Surg Gynaecol Obstet 1991, 173:123-130.
10. Xiao Z.F., Yang Z.Y., Liang J., et al. Value of radiotherapy after radical surgery for oesophageal carcinoma: a report of 495 patients. Ann Thoracic Surg 2003, 75:331-336.
11. Tachibana M., Yoshimura H., Kinugasa S., et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol 2003, 29:580-587.
12. Liu H.-C., Hung S.-K., Huang C.-J., et al. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005, 11:5367-5372.
13. Apinop C., Puttisak P., Preecha N. A prospective study of combined therapy in oesophageal cancer. Hepato-Gastroenterology 1994, 41:391-393.
14. Walsh T.N., Grennell M., Mansoor S., et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus 2002, 15:121-124.
15. Bosset J., Gignoux M., Triboulet J., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell carcinoma of the oesophagus. N Engl J Med 1997, 337:161-167.
16. Lee J., Park S., Kim S., et al. A single institutional phase 3 trial of preoperative chemotherapy with hyperfraction radiotherapy plus surgery versus surgery alone for resectable squamous cell carcinoma. Ann Oncol 2004, 15:947-954.
17. Burmeister B., Smithers B., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase 3 trial. Lancet Oncol 2005, 6:659-668.
18. Carstens H., Albertsson M., Friesland S., et al. A randomised trial of chemoradiotherapy versus surgery alone in patients with resectable oesophgeal cancer (abstract). J Clin Oncol 2007, 25:205.
19. Urba S., Orringer M., Turrisi A., et al. Randomised trial of preoperative chemoradiation versus surgery alone in patients with locoregional oesophageal carcinoma. J Clin Oncol 2001, 19:305.
20. Tepper J., Krasna M., Niedwiecki D., et al. Phase 3 trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for oesophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
21. Cao X.F., He X.T., Ji L., et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 2009, 22:477-481.
22. Zheng B., Zheng W., Zhu Y., et al. Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis. Chinese Med J 2013, 126:1178-1182.
23. Wang D.-B., Zhang X., Han H.-L., et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Digest Dis Sci 2012, 57:3226-3233.
24. Sjoquist K., Burmeister B., Smithers M., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681-692.
25. Malthaner R.A., Wong R.K., Rumble R.B., et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004, 2:35.
26. Saito T., Shigemitsu Y., Kinoshita T., et al. Cisplatin, vindesine, pepleomycin and concurrent radiation therapy following esophagectomy with lymph adenectomy for patients with an esophageal carcinoma. Oncology 1993, 50:293-297.
27. Mukaida H., Hirai T., Yamashita Y., et al. Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer. Japan J Thoracic Cardiovasc Surg 1998, 46:11-17.
28. Eric L., Inculet R., Malthaner R., et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001, 91:2423-2430.
29. Rice T.W., Adelstein D.J., Chidel M.A., et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thoracic Cardiovasc Surg 2003, 126:1590-1596.
30. Cao X., Lu J., Zhu B., et al. A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Chinese J Oncol 2010, 32:452-455.
31. Berger B., Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol 2009, 92:276-290.
32. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
33. Allum W.H.B.J., Griffin S.M., Cunningham D., et al. Guidelines for the management of oesopahgeal and gastric cancer. Gut 2011, 60:1449-1472.
34. Winjhoven B., van Lanschot J., Tilanus H., et al. Neoadjuvant chemoradiotherapy for eosophageal cancer: a review of meta-analyses. World J Surg 2009, 33:2606-2614.
35. Gwynne S., Hurt C., Evans M., et al. Definitive chemoradiation for oesophageal cancer - a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol 2011, 23:182-188.
36. Crosby T., Hurt C.N., Falk S., et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013, 14:627-637.
37. van Heijl M., van Lanschot J.J.B., Koppert L.B., et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008, 8:21.
38. Matzinger O., Gerber E., Bernstein Z., et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009, 92:164-175.
39. Courrech Staal E.F.W., Aleman B.M.P., Boot H., et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010, 97:1482-1496.
40. Allum W.H.B.J., Griffin S.M., Cunningham D., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067.
41. Luu T.D., Gaur P., Force S.D., et al. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann Thoracic Surg 2008, 85:1217-1223. discussion 1223-1224.
42. Stahl M., Walz M., Stuschke M., et al. Phase 3 comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851.
43. Burmeister B.H., Thomas J.M., Burmeister E.A., et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011, 47:354-360.
44. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cell carcinoma of the oesophagus. J Clin Oncol 2007, 25:1160-1168.
45. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
46. Maas M., Beets-Tan R.G., Lambregts D.M., et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011, 29:4633-4640.
47. Habr-Gama A., Sabbaga J., Gama-Rodrigues J., et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?. Dis Colon Rectum 2013, 56:1109-1117.
48. Marks J.L., Hofstetter W., Correa A.M., et al. ACe: salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thoracic Surg 2012, 94:1126-1132.
49. Piessen G., Petyt G., Duhamel A., et al. Ineffectiveness of F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2013, 258:66.
50. Leichman L.P., Goldman B.H., Bohanes P.O., et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011, 29:4555-4560.
51. Hsu P., Chien L., Huang C., et al. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit at all?. Interactive Cardiovasc Thoracic Surg 2013, http://dx.doi.org/10.1093/icvts/ivt216.
52. Noble F., Nolan L., Bateman A.C., et al. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013, 19:9282-9293.
53. Bendell J.C., Meluch A., Peyton J., et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012, 10:430-437.
54. Lee M.S., Mamon H.J., Hong T.S., et al. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist 2013, 18:281-287.
55. Zum Buschenfelde C.M., Herrmann K., Schuster T., et al. F-18-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011, 52:1189-1196.